Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
This page provides a historical news archive for ZimVie Inc. (formerly Nasdaq: ZIMV), a company that described itself as a global life sciences leader in the dental and dental implant market. The news coverage reflects ZimVie’s activities while it was a publicly traded manufacturer and developer of dental implants, biomaterials, and digital workflow solutions for tooth replacement and restoration procedures.
Readers can review company-issued announcements on topics such as quarterly financial results, strategic agreements, product launches, and corporate transactions. For example, ZimVie reported first and second quarter 2025 financial results, including net sales from continuing operations and non-GAAP measures like adjusted EBITDA and adjusted diluted earnings per share. The company also communicated guidance for full-year financial performance while it remained public.
The archive includes news about ZimVie’s role in digital dentistry, such as the launch of the RealGUIDE dental implant software suite and the Implant Concierge service in Japan. These releases describe a digital implant ecosystem that supports implant planning, surgical guide design, and restorative workflows, as well as virtual outsourcing services for implant treatment planning and guided surgery. Other news items highlight an exclusive distribution agreement with Osstem Implant in China, under which Osstem Implant has exclusive commercial responsibility for ZimVie implant systems in the Chinese market.
A significant portion of the news flow in 2025 relates to ZimVie’s agreement to be acquired by an affiliate of ARCHIMED. The company announced the definitive merger agreement, subsequent stockholder approval at a special meeting, and the completion of the transaction. In its October 20, 2025 release, ZimVie stated that, following the closing of the acquisition, its common stock no longer trades on the Nasdaq exchange and the company became privately held. Investors and researchers can use this news history to understand ZimVie’s strategic direction, financial communication, and the steps leading to its transition from a listed company to a private entity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ZimVie Inc. (Nasdaq: ZIMV) has launched its latest educational facility, the ZimVie Institute South, in Palm Beach Gardens, Florida. This state-of-the-art center spans over 11,000 sq. ft. and is designed for hands-on dental training. It features advanced training spaces including life-like simulated patient models, a cadaver lab, and a fully integrated digital workflow incorporating 3D printing and RealGUIDE™ software.
The facility aims to enhance professional development for dental practitioners, with plans to accommodate over 1,500 dental professionals annually. ZimVie currently trains over 100,000 dental professionals worldwide through its six institutes and virtual programs. This initiative reflects ZimVie’s commitment to leading advancements in dental education and innovation.
ZimVie has launched two new dental biomaterials, the RegenerOss CC Allograft Particulate and RegenerOss Bone Graft Plug, expanding its portfolio of bone graft solutions for dental applications. These products aim to fill bony voids and assist in dental procedures, enhancing ZimVie's presence in the dental biomaterials market. The RegenerOss solutions complement ZimVie's existing Puros Allograft line, which is known for its clinical efficacy. Indraneel Kanaglekar, SVP and President of ZimVie Dental, emphasized the company’s commitment to innovation and expanding its product offerings to meet customer needs.
Founded in March 2022, ZimVie focuses on the dental and spine markets and serves customers in over 70 countries with an extensive portfolio of clinically supported products.
ZimVie Inc. (Nasdaq: ZIMV) will release its first quarter 2023 financial results on May 3, 2023, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time to discuss the results. Interested participants can register in advance to listen to the call, and an archived replay will be available afterwards on the company’s investor relations website. Founded as a spin-off from Zimmer Biomet in March 2022, ZimVie specializes in the dental and spine markets, providing a range of innovative products aimed at treating spine pathologies and aiding dental procedures. With operations in over 70 countries, ZimVie aims to leverage extensive clinical evidence to support its diversified product portfolio.